SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma

Oncogene

Volumn 33, Issue 42, 2014, Pages 5006-5016

  Trautmann, M ^a,b   Sievers, E ^a   Aretz, S ^c   Kindler, D ^a   Michels, S ^a   Friedrichs, N ^a   Renner, M ^d   Kirfel, J ^b   Steiner, S ^b   Huss, S ^a   Koch, A ^e   Penzel, R ^d   Larsson, O ^f   Kawai, A ^g   Tanaka, S ^h   Sonobe, H ⁱ   Waha, A ^b   Schirmacher, P ^d   Mechtersheimer, G ^d   Wardelmann, E ^a   Buttner R ^a   Hartmann, W ^a   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f KAROLINSKA INSTITUTE   (Sweden)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ Chungoku Central Hospital   (Japan)

Author keywords

CGP049090; PKF115 584; PKF118 310; Synovial sarcoma; SYT SSX; Wnt signaling pathway; catenin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CGP049090; CTNNB1 PROTEIN, HUMAN; ONCOPROTEIN; PERYLENE; PKF115-584; PKF118-310; PYRIMIDINONE DERIVATIVE; SS18-SSX1 FUSION PROTEIN; SYT-SSX FUSION PROTEIN; TRIAZINE DERIVATIVE;

ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL NUCLEUS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; NUDE MOUSE; PHYSIOLOGY; SARCOMA, SYNOVIAL; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; GENE EXPRESSION; HEK293 CELLS; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; ONCOGENE PROTEINS, FUSION; PERYLENE; PYRIMIDINONES; SARCOMA, SYNOVIAL; TRIAZINES; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85028161136     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.443     Document Type: Article

References (52)

1. Weiss SW, Goldblum JR, Folpe AL Enzinger and Weiss's Soft Tissue Tumors Elsevier Health Sciences 2007.
2. Turc-Carel C, Dal Cin P, Limon J, Li F, Sandberg AA. Translocation X;18 in synovial sarcoma. Cancer Genet Cytogenet 1986; 23: 93. DOI: 10.1016/0165-4608(86)90153-6
3. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7: 502–508. DOI: 10.1038/ng0894-502
4. Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res 2008; 466: 2156–2167. DOI: 10.1007/s11999-008-0340-2
5. Soulez M, Saurin AJ, Freemont PS, Knight JC. SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex. Oncogene 1999; 18: 2739–2746. DOI: 10.1038/sj.onc.1202613
6. Nagai M, Tanaka S, Tsuda M, Endo S, Kato H, Sonobe H et al. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci USA 2001; 98: 3843–3848. DOI: 10.1073/pnas.061036798
7. de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, van Groningen JJ et al. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 2006; 66: 9474–9482. DOI: 10.1158/0008-5472.CAN-05-3726
8. Garcia CB, Shaffer CM, Eid JE. Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2. BMC Genomics 2012; 13: 189. DOI: 10.1186/1471-2164-13-189
9. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002; 359: 1301–1307. DOI: 10.1016/S0140-6736(02)08270-3
10. Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 2002; 62: 5859–5866.
11. Segal NH, Pavlidis P, Antonescu CR, Maki RG, Noble WS, DeSantis D et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003; 163: 691–700. DOI: 10.1016/S0002-9440(10)63696-6
12. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005; 65: 9226–9235. DOI: 10.1158/0008-5472.CAN-05-1699
13. Francis P, Namlos HM, Muller C, Eden P, Fernebro J, Berner JM et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007; 8: 73. DOI: 10.1186/1471-2164-8-73
14. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5: 997–1014. DOI: 10.1038/nrd2154
15. Clevers H, Nusse R. Wnt/β-Catenin Signaling and Disease. Cell 2012; 149: 1192–1205. DOI: 10.1016/j.cell.2012.05.012
16. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8: 387–398. DOI: 10.1038/nrc2389
17. Vijayakumar S, Liu G, Rus IA, Yao S, Chen Y, Akiri G et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/beta-catenin target gene, CDC25A. Cancer Cell 2011; 19: 601–612. DOI: 10.1016/j.ccr.2011.03.010
18. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11–26. DOI: 10.1038/nrc3419
19. Saito T, Oda Y, Sakamoto A, Tamiya S, Kinukawa N, Hayashi K et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 2000; 192: 342–350. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-R
20. Saito T, Oda Y, Sakamoto A, Kawaguchi K, Tanaka K, Matsuda S et al. APC mutations in synovial sarcoma. J Pathol 2002; 196: 445–449. DOI: 10.1002/path.1066
21. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42: 715–721. DOI: 10.1038/ng.619
22. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004; 5: 91–102. DOI: 10.1016/S1535-6108(03)00334-9
23. Trosset JY, Dalvit C, Knapp S, Fasolini M, Veronesi M, Mantegani S et al. Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins 2006; 64: 60–67. DOI: 10.1002/prot.20955
24. Zhang M, Catrow JL, Ji H. High-Throughput Selectivity Assays for Small-Molecule Inhibitors of β-Catenin/T-Cell Factor Protein–Protein Interactions. ACS Med Chem Lett 2013; 4: 306–311. DOI: 10.1021/ml300367f
25. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007; 67: 1979–1987. DOI: 10.1158/0008-5472.CAN-06-1479
26. Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, Repich K et al. CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One 2010; 5: e8979. DOI: 10.1371/journal.pone.0008979
27. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837–847. DOI: 10.1016/S0092-8674(02)00685-2
28. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006; 281: 9971–9976. DOI: 10.1074/jbc.M508778200
29. Provost E, McCabe A, Stern J, Lizardi I, D'Aquila TG, Rimm DL. Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin. Oncogene 2005; 24: 2667–2676. DOI: 10.1038/sj.onc.1208346
30. Romagnolo B, Berrebi D, Saadi-Keddoucci S, Porteu A, Pichard AL, Peuchmaur M et al. Intestinal dysplasia and adenoma in transgenic mice after overexpression of an activated beta-catenin. Cancer Res 1999; 59: 3875–3879.
31. Pretto D, Barco R, Rivera J, Neel N, Gustavson MD, Eid JE. The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene 2006; 25: 3661–3669. DOI: 10.1038/sj.onc.1209413
32. Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 2008; 68: 4303–4310. DOI: 10.1158/0008-5472.CAN-08-0092
33. Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, Schlosser A et al. Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 2010; 12: 326–335. DOI: 10.1593/neo.91972
34. Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer 2010; 126: 2426–2436.
35. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007; 11: 375–388. DOI: 10.1016/j.ccr.2007.01.016
36. Haldar M, Hedberg ML, Hockin MF, Capecchi MR. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res 2009; 69: 3657–3664. DOI: 10.1158/0008-5472.CAN-08-4127
37. Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005; 18: 68–74. DOI: 10.1038/modpathol.3800272
38. Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T, Hirohashi S. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol 2001; 32: 257–263. DOI: 10.1053/hupa.2001.22764
39. Sato H, Hasegawa T, Kanai Y, Tsutsumi Y, Osamura Y, Abe Y et al. Expression of cadherins and their undercoat proteins (alpha-, beta-, and gamma-catenins and p120) and accumulation of beta-catenin with no gene mutations in synovial sarcoma. Virchows Arch 2001; 438: 23–30. DOI: 10.1007/s004280000318
40. Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012; 21: 333–347. DOI: 10.1016/j.ccr.2012.01.010
41. Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013; 153: 71–85. DOI: 10.1016/j.cell.2013.02.036
42. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008; 283: 17969–17978. DOI: 10.1074/jbc.M802917200
43. Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K et al. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010; 28: 1119–1131.
44. Friedrichs N, Kriegl L, Poremba C, Schaefer KL, Gabbert HE, Shimomura A et al. Pitfalls in the detection of t(11;22) translocation by fluorescence in situ hybridization and RT-PCR: a single-blinded study. Diagn Mol Pathol 2006; 15: 83–89. DOI: 10.1097/00019606-200606000-00004
45. Nojima T, Wang YS, Abe S, Matsuno T, Yamawaki S, Nagashima K. Morphological and cytogenetic studies of a human synovial sarcoma xenotransplanted into nude mice. Acta Pathol Jpn 1990; 40: 486–493.
46. Sonobe H, Manabe Y, Furihata M, Iwata J, Oka T, Ohtsuki Y et al. Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. Lab Invest 1992; 67: 498–505.
47. Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, Shimizu K et al. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett 2004; 204: 105–113. DOI: 10.1016/j.canlet.2003.09.031
48. Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P et al. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 2008; 216: 428–439. DOI: 10.1002/path.2438
49. Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M et al. SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer Res 2013; 73: 2518–2528. DOI: 10.1158/0008-5472.CAN-12-3023
50. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science 1997; 275: 1784–1787. DOI: 10.1126/science.275.5307.1784
51. Nguyen A, Su L, Campbell B, Poulin NM, Nielsen TO. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma 2009; 2009: 794901. DOI: 10.1155/2009/794901
52. Webb JL. Enzyme and Metabolic Inhibitors. Academic Press, New York, USA, 1966.